



ASX ANNOUNCEMENT

16 March 2015

Cynata Renews Management Contracts & Final Director Options Vest

..Contracts renewed for Dr Ross Macdonald and Dr Stewart Washer on same terms as current contracts that expire in July 2015

..Final tranche of Director Options vest

Melbourne, Australia, 16 March 2015: The Board of stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), wishes to advise that the executive services contracts for the Chief Executive Officer and Managing Director, Dr Ross Macdonald and Executive Chairman, Dr Stewart Washer have been renewed on the same terms and conditions as the current contracts that expire at the end of July 2015, with a new termination date of end June 2017.

Also, the following vesting condition has been met on the final tranche of unlisted 27 September 2018 \$0.40 Director Options for Dr Stewart Washer and Dr Ross Macdonald:

Tranche	Number of Options	Vesting Condition
C	500,000 each	The volume weighted average price of shares over a period of 10 consecutive trading days being at least \$1.20 per share.

The unlisted 27 September 2018 Director Options, which were issued in September 2013, are subject to escrow until 27 November 2015.

Ends.

Further Inquiries:

Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com

Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com



About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA technology provides a consistent, reliable source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.